Press release from Companies: Curasight strengthens its strategic position with the acquisition of TRT Innovations ApS

Press release from Companies: Phase II study of uPAR-PET in neuroendocrine tumor patients demonstrates strong prognostic value and supports potential future use of uPAR-targeted radionuclide therapy

Press release from Companies: Curasight presents at the SEB Nordic Healthcare Seminar 2022 and at Kapital Partner

Press release from Companies: Curasight attends the J.P. Morgan Healthcare Conference and presents at HC Andersen Capital

Press release from Companies: Curasight attends the J.P. Morgan Healthcare Conference and presents at HC Andersen Capital

Press release from Companies: Hanne Damgaard Jensen joins Curasight A/S as Chief Development Officer (CDO)

Press release from Companies: Transaction with shares in Curasight A/S made by managerial employee

Press release from Companies: Curasight presents at HC Andersen Capital

Press release from Companies: Curasight presents at HC Andersen Capital

Press release from Companies: Curasight presents at HC Andersen Capital

Press release from Companies: Phase II study demonstrates prognostic value of uPAR-PET in head and neck cancer patients

Press release from Companies: Curasight A/S presents at HC Andersen Capital & Nordea Markets Virtual Growth Days seminar - 9 December 2021